Literature DB >> 16682964

mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis.

Carl Rios1, Ivone Gomes, Lakshmi A Devi.   

Abstract

Several studies have described functional interactions between opioid and cannabinoid receptors; the underlying mechanism(s) have not been well explored. One possible mechanism is direct receptor-receptor interactions, as has been demonstrated for a number of G-protein-coupled receptors. In order to investigate interactions between opioid and cannabinoid receptors, we epitope tagged mu, delta and kappa opioid receptors with Renilla luciferase and CB1 cannabinoid or CCR5 chemokine receptors with yellow fluorescent protein and examined the extent of substrate hydrolysis induced bioluminescence resonance energy transfer (BRET) signal. We find that coexpression of opioid receptors with cannabinoid receptors, but not with chemokine receptors, leads to a significant increase in the level of BRET signal, suggesting that the opioid-cannabinoid interactions are receptor specific. In order to examine the implications of these interactions to signaling, we used GTPgammaS binding and mitogen-activated protein kinase (MAPK) phosphorylation assays and examined the effect of receptor activation on signaling. We find that the mu receptor-mediated signaling is attenuated by the CB1 receptor agonist; this effect is reciprocal and is seen in heterologous cells and endogenous tissue expressing both receptors. In order to explore the physiological consequences of this interaction, we examined the effect of receptor activation on the extent of Src and STAT3 phosphorylation and neuritogenesis in Neuro-2A cells. We find that the simultaneous activation of mu opioid and CB1 cannabinoid receptors leads to a significant attenuation of the response seen upon activation of individual receptors, implicating a role for receptor-receptor interactions in modulating neuritogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682964      PMCID: PMC1751792          DOI: 10.1038/sj.bjp.0706757

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

Review 1.  G-protein-coupled receptor dimerization: modulation of receptor function.

Authors:  C D Rios; B A Jordan; I Gomes; L A Devi
Journal:  Pharmacol Ther       Date:  2001 Nov-Dec       Impact factor: 12.310

2.  Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines.

Authors:  Venugopalan D Nair; C Warren Olanow; Stuart C Sealfon
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

Review 3.  Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example.

Authors:  James Wager-Miller; Ruth Westenbroek; Ken Mackie
Journal:  Chem Phys Lipids       Date:  2002-12-31       Impact factor: 3.329

4.  The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer.

Authors:  Wen Guo; Lei Shi; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2002-12-19       Impact factor: 5.157

Review 5.  Oligomerization of opioid receptors.

Authors:  Ivone Gomes; Julija Filipovska; Bryen A Jordan; Lakshmi A Devi
Journal:  Methods       Date:  2002-08       Impact factor: 3.608

6.  Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation.

Authors:  Wen Guo; Lei Shi; Marta Filizola; Harel Weinstein; Jonathan A Javitch
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

7.  Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors.

Authors:  Sandy Ghozland; Hans W D Matthes; Frederic Simonin; Dominique Filliol; Brigitte L Kieffer; Rafael Maldonado
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

Review 8.  International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Authors:  A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; R Mechoulam; R G Pertwee
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

9.  Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein.

Authors:  Jean-Louis Banères; Joseph Parello
Journal:  J Mol Biol       Date:  2003-06-13       Impact factor: 5.469

10.  c-Src protein tyrosine kinase activity is required for muscarinic receptor-mediated DNA synthesis and neurogenesis via ERK1/2 and c-AMP-responsive element-binding protein signaling in neural precursor cells.

Authors:  Wei-Qin Zhao; Daniel L Alkon; Wu Ma
Journal:  J Neurosci Res       Date:  2003-05-01       Impact factor: 4.164

View more
  125 in total

1.  Receptor-regulated interaction of activator of G-protein signaling-4 and Galphai.

Authors:  Sukru Sadik Oner; Ellen M Maher; Billy Breton; Michel Bouvier; Joe B Blumer
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Consequences of opioid receptor mutation on actions of univalent and bivalent kappa and delta ligands.

Authors:  Michael A Ansonoff; Philip S Portoghese; John E Pintar
Journal:  Psychopharmacology (Berl)       Date:  2010-03-24       Impact factor: 4.530

Review 3.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Authors:  Brian D Hudson; Terence E Hébert; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 5.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 6.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

7.  β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4.

Authors:  Thomas J LaRocca; Martina Schwarzkopf; Perry Altman; Shihong Zhang; Achla Gupta; Ivone Gomes; Zikiar Alvin; Hunter C Champion; Georges Haddad; Roger J Hajjar; Lakshmi A Devi; Alison D Schecter; Sima T Tarzami
Journal:  J Cardiovasc Pharmacol       Date:  2010-11       Impact factor: 3.105

8.  AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Authors:  Kathryn A Seely; Lisa K Brents; Lirit N Franks; Maheswari Rajasekaran; Sarah M Zimmerman; William E Fantegrossi; Paul L Prather
Journal:  Neuropharmacology       Date:  2012-07-04       Impact factor: 5.250

9.  GPR171 is a hypothalamic G protein-coupled receptor for BigLEN, a neuropeptide involved in feeding.

Authors:  Ivone Gomes; Dipendra K Aryal; Jonathan H Wardman; Achla Gupta; Khatuna Gagnidze; Ramona M Rodriguiz; Sanjai Kumar; William C Wetsel; John E Pintar; Lloyd D Fricker; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

10.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.